Successful treatment with a long-acting somatostatin analogue (SMS201-995) in a patient with malignant carcinoid syndrome.

Abstract

A case of carcinoid syndrome is presented. Pulmonary adenosquamous carcinoma with hepatic metastasis was found in a 60-year-old Japanese male who was complaining of fever, cough and haemosputum. After the treatment with 5-fluorouracil (5-FU) over 2 years, he was diagnosed as carcinoid syndrome on the appearance of facial flushing, face edema and watery diarrhea accompanied by high levels of 5-hydroxyindole acetic acid (5-HIAA) in blood and urine. Prednisolone, which was initially effective, was replaced by SMS201-995 due to the considerable dose increase of the former because its effect became insufficient during the course of the treatment. Clinical symptoms were improved by SMS201-995 and blood 5-HIAA level decreased gradually but markedly. Thus better results were obtained by SMS201-995 compared with prednisolone. These results imply that SMS201-995 is appreciated as an effective drug for treatment of carcinoid syndrome.

• Authors: M Tsuda, S Tamaki, E Iwasaki, S Murashima, K Deguchi, S Shirakawa
• Journal: Japanese journal of medicine (Jpn J Med) Vol. 27 Issue 3 Pg. 311-6 (Aug 1988) ISSN: 0021-5120 [Print] Japan
• PMID: 3193661 (Publication Type: Case Reports, Comparative Study, Journal Article)

Chemical References

• Delayed-Action Preparations
• Prednisolone
• Octreotide

Topics

• Adenocarcinoma (drug therapy)
• Carcinoma, Squamous Cell (drug therapy)
• Delayed-Action Preparations
• Humans
• Liver Neoplasms (drug therapy, secondary)
• Lung Neoplasms (drug therapy)
• Male
• Malignant Carcinoid Syndrome (drug therapy, metabolism)
• Middle Aged
• Octreotide (therapeutic use)
• Prednisolone (administration & dosage, therapeutic use)